Skip to main content
. Author manuscript; available in PMC: 2022 Nov 15.
Published in final edited form as: J Immunol. 2021 Oct 8;207(10):2589–2597. doi: 10.4049/jimmunol.2100766

Figure 8: IL-4 is required for atopic protection from post-viral airway disease.

Figure 8:

Atopic mice were treated with anti-IL-4 (clone 1B11) or control mAb (1.5 mg, i.p.) 24 hours before inoculation with SeV. (A) Blockade of IL-4 led to restoration of AHR by d21 PI SeV, n=3. (B) Restoration of post-viral airway disease was associated with a trend for increased SeV titer in whole lung of anti-IL-4 treated mice 1 day PI SeV. (C) However, no difference was seen in the quantity of hybrid PMN-DC cells with IL-4 blockade. (D) Culture of PMN with IL-4 for 90 min led to increased phagocytic activity in vitro, as evidenced by increased Zymosan uptake.